CDT_OUT_1 [2025-04-02 08:39:14 -0400] 2984 Bytes | 749 tokens | Cum: 749 tkns (9.36% of 8k)
==========================================================================

Alright, let’s light it up, because it's 8:39:14 AM on Wed Apr 02, 2025 -0400, and I'm charging into Conduit Pharmaceuticals (CDT), popping from 0.7221 to 0.825. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Conduit Pharmaceuticals (CDT)
IPO: 2023-09-25 (1 Year Ago)
Market Cap: $4,474,581
Shares Outstanding: 6,660,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Here's the first list of news for Conduit Pharmaceuticals:

C1 - Mar-31-25 08:30AM - Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
C2 - Mar-19-25 08:30AM - Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
C3 - Mar-07-25 04:53AM - Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?
C4 - Mar-06-25 09:35AM - Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
C5 - Feb-20-25 08:00AM - Conduit Progresses Phase II of its AI Initiative with Sarborg
C6 - Feb-13-25 08:00AM - Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
C7 - Feb-11-25 09:00AM - Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
C8 - Feb-08-25 06:08AM - Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase II

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Conduit Pharmaceuticals (CDT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CDT_OUT_3 [2025-04-02 08:39:19 -0400] 1102 Bytes | 323 tokens | Cum: 1074 tkns (13.43% of 8k)
==========================================================================

Showing C1 (chunk 1 of 7): C1:
**Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases**
Date: Mar-31-25 08:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052279/0/en/Conduit-Pharmaceuticals-Receives-U-S-Patent-Approval-For-Its-Lead-Asset-Targeting-Autoimmune-Diseases.html

March 31, 2025 08:30 ET| Source:Conduit PharmaceuticalsConduit Pharmaceuticals

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that the United States Patent and Trademark Office (USPTO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent protection

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CDT_OUT_5 [2025-04-02 08:39:20 -0400] 1010 Bytes | 296 tokens | Cum: 1458 tkns (18.22% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T20:54:43Z - Presidio Property Trust, Inc. Announces Earnings for the Year Ended December 31, 2024...
A2 - 2025-03-31T20:56:59Z - Presidio Property Trust, Inc. Announces Earnings for the Year Ended December 31, 2024 | Taiwan News ...
A3 - 2025-03-31T20:30:00Z - Presidio Property Trust, Inc. Announces Earnings for the Year Ended December 31, 2024 - Presidio Pro...
A4 - 2025-03-31T13:20:42Z - Conduit Pharma's AZD1656 Receives US Patent Approval For Autoimmune Diseases Treatment...
A5 - 2025-03-31T12:48:51Z - Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseas...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CDT_OUT_7 [2025-04-02 08:39:22 -0400] 321 Bytes | 94 tokens | Cum: 1554 tkns (19.43% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1):

[INFO] Your document request exceeded 20000 characters. If you need more, please request additional documents separately.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CDT_OUT_9 [2025-04-02 08:39:23 -0400] 955 Bytes | 286 tokens | Cum: 1871 tkns (23.39% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-01T20:45:00Z - Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
B2 - 2024-07-17T10:03:31Z - Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
B3 - 2024-07-16T21:05:30Z - What Happened With Conduit Pharmaceuticals (CDT) Stock Today? - Benzinga
B4 - 2024-07-16T09:51:08Z - Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
B5 - 2024-03-11T11:00:00Z - Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
B6 - 2023-12-28T15:53:18Z - NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CDT_OUT_11 [2025-04-02 08:39:26 -0400] 826 Bytes | 216 tokens | Cum: 2089 tkns (26.11% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/01/2973572/0/en/Conduit-Pharmaceuticals-Announces-Debt-Restructuring-and-Additional-Notes.htmlConduit Pharmaceuticals has restructured a $2.65 million loan note with Nirland Limited, removing restrictive clauses and making the note convertible. The company has also secured $1.2 million in new promissory notes, positioning it to access its At-The-Market (ATM) facility to support its note repayment obligations, operations, and clinical objectives.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CDT_OUT_13 [2025-04-02 08:39:27 -0400] 1111 Bytes | 291 tokens | Cum: 2456 tkns (30.70% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S5 - 2025-03-28 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read together with the other sections of this Annual Report on Form 10-K, including...

S6 - 2025-01-23 8-K Item 7.01. Regulation FD Disclosure.

On January 23, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1 atta...

S7 - 2024-12-17 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On December 12, 2024, Conduit Pharmaceuticals Inc. (Conduit) entered into a Services Agrmt (the Agrmt) with SARBORG Limited (Sarborg), a Cayman Islands company. Under the terms of the Agrmt, Sarborg will provide ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CDT_OUT_15 [2025-04-02 08:39:28 -0400] 1098 Bytes | 228 tokens | Cum: 2686 tkns (33.58% of 8k)
==========================================================================

Showing S5 (chunk 1 of 6): S5:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with the other sections of this Annual Report on Form 10-K, including our audited financial statements for the year ended December 31, 2024, together with related notes thereto, included elsewhere in this Annual Report. The following discussion contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled Risk Factors or in other parts of this Annual Report and our other filings with the SEC. Our historical results are not necessarily indica

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CDT_OUT_17 [2025-04-02 08:39:29 -0400] 1098 Bytes | 265 tokens | Cum: 2953 tkns (36.91% of 8k)
==========================================================================

Showing S5 (chunk 2 of 6): tive of the results that may be expected for any period in the future. Conduit Pharmaceuticals Limited entered into an Agreement and Plan of Merger (the Merger Agreement) with Murphy Canyon Acquisition Corp. (MURF) on November 8, 2022. The transaction contemplated by the terms of the Merger Agreement was completed on September 22, 2023, in conjunction with which MURF changed its name to Conduit Pharmaceuticals Inc. (hereafter referred to, collectively with is subsidiaries as Conduit, the Company, we, us or our, unless the context otherwise requires. All dollar amounts are expressed in thousands of United States dollars ($), unless otherwise indicated.

Overview

On September 22, 2023, a merger transaction (the Business Combination) between Conduit Pharmaceuticals Limited (Old Conduit), Murphy Canyon Acquisition Corp (MURF) and Conduit Merger Sub, Inc., a Cayman Islands exempted company

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CDT_OUT_19 [2025-04-02 08:39:38 -0400] 4692 Bytes | 1394 tokens | Cum: 4349 tkns (54.36% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+------------------------+------------------------+-------------------+
| Volume: 3,337,058 | Perf Month: -37.75% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+------------------------+------------------------+-------------------+
| Avg Volume: 3.94M | Perf Quarter: -87.99% | Short Float: 17.68% | ROE: -89.65% |
+--------------------+------------------------+------------------------+-------------------+
| Rel Volume: 0.82 | Index: RUT | Short Ratio: 0.19 | ROI: - |
+--------------------+------------------------+------------------------+-------------------+
| RSI (14): 32.32 | Market Cap: 4.81M | Short Interest: 0.75M | Sales Surprise: - |
+--------------------+------------------------+------------------------+-------------------+
| ATR (14): 0.24 | Shs Outstand: 4.71M | Beta: 2.35 | EPS Surprise: - |
+--------------------+------------------------+------------------------+-------------------+
| SMA20: -24.27% | Shs Float: 4.25M | Sales Q/Q: - | P/E: - |
+--------------------+------------------------+------------------------+-------------------+
| SMA50: -58.84% | Inst Own: 1.86% | Sales past 5Y: 0.00% | Earnings: - |
+--------------------+------------------------+------------------------+-------------------+
| SMA200: -96.20% | Insider Own: 9.71% | Employees: 6 | |
+--------------------+------------------------+------------------------+-------------------+
| Perf Week: -12.09% | Insider Trans: -90.84% | Debt/Eq: - | |
+--------------------+------------------------+------------------------+-------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: CONDUIT PHARMACEUTICALS INC. (CDT) by Charles Faith L. (Unknown Title) on 2025-03-30
- Common Stock: 46629 shares at $0.89 (D)

Inside Trans: CONDUIT PHARMACEUTICALS INC. (CDT) by Farley Chele Chiavacci (Unknown Title) on 2025-03-30
- Common Stock: 32022 shares at $0.89 (D)

Inside Trans: CONDUIT PHARMACEUTICALS INC. (CDT) by Fry Simon Jeremy (Unknown Title) on 2025-03-30
- Common Stock: 29354 shares at $0.89 (D)

Inside Trans: CONDUIT PHARMACEUTICALS INC. (CDT) by Lewis-Hall Freda C (Unknown Title) on 2025-03-30
- Common Stock: 47612 shares at $0.89 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -17802000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.7221
Average Volume: 1769826.68
30-Day High: 1.16
30-Day Low: 0.7221

[Detailed Financials: TTM 2024]
- Total Assets: $4,193,000.0
- Total Liabilities: $10,986,000.0
- Total Equity: $-6,793,000.0
- Current Assets: $2,715,000.0
- Current Liabilities: $10,741,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -20.53

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-3,658,000.0

[Detailed Financials: FY 2024]
- Total Assets: $4,193,000.0
- Total Liabilities: $10,986,000.0
- Total Equity: $-6,793,000.0
- Current Assets: $2,715,000.0
- Current Liabilities: $10,741,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -20.53

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-3,658,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CDT_OUT_21 [2025-04-02 08:39:41 -0400] 676 Bytes | 167 tokens | Cum: 4761 tkns (59.51% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CDT_IN_23 [2025-04-02 08:39:41 -0400] 126 Bytes | 29 tokens | Cum: 4845 tkns (60.56% of 8k)
==========================================================================

====================================
[2025-04-02 08:39:41] # Analysis Completed
Elapsed Time: 27.50 seconds